Definition And Etiology
- Autosomal recessive disorders of sulfur amino acid metabolism characterized by the accumulation of homocysteine in blood and urine.
- Classic Homocystinuria results from a deficiency of Cystathionine $\beta$-Synthase (CBS), requiring Vitamin B6 as a cofactor.
- Other forms result from defects in homocysteine remethylation, such as Methylene Tetrahydrofolate Reductase (MTHFR) deficiency or Cobalamin (Vitamin B12) processing defects.
%%{init: {"theme": "base", "themeVariables": { "lineWidth": "3px", "lineColor": "#000000", "primaryColor": "#e1f5fe", "primaryBorderColor": "#01579b", "primaryTextColor": "#01579b" }}}%%
graph TD
DA[Dietary Amino Acids] --> MET[Methionine]
MET --> HC[Homocysteine]
%% The Blocked Pathway
HC -- "Cystathionine β-synthase (CBS) <br/> (Pyridoxine-dependent)" --- BLOCK{X}
BLOCK --> CYSTATH[Cystathionine]
CYSTATH --> CYS[Cysteine]
%% Remethylation Pathways (Back to Methionine)
HC -- "Folate <br>/ B12 <br>dependent" --> MET
HC -- "Betaine (Alternative Pathway)" --> MET
%% Styling specific nodes
style BLOCK fill:#ffebee,stroke:#c62828,stroke-width:4px,color:#c62828
style DA fill:#f1f8e9,stroke:#33691e,color:#33691e
style CYS fill:#f1f8e9,stroke:#33691e,color:#33691e
Pathophysiology
Biochemical Defect
| Defect Type | Enzyme/Cofactor | Biochemical Consequences |
|---|---|---|
| Classic | Cystathionine $\beta$-Synthase (CBS), Vitamin B6 | Failure to convert homocysteine to cystathionine. Leads to elevated homocysteine, elevated methionine, and low cysteine (cysteine becomes an essential amino acid). |
| Remethylation | MTHFR, Methionine Synthase, Vitamin B12 | Failure to convert homocysteine back to methionine. Leads to elevated homocysteine and low methionine. |
Mechanism Of Toxicity
- Elevated homocysteine causes severe endothelial injury, leading to a high risk of thrombosis.
- Elevated metabolites interfere with collagen and elastin cross-linking via fibrillin-1 inhibition.
- Homocysteine acts as an NMDA receptor agonist, leading to neurotoxicity and seizures.
Clinical Features
Patients typically appear normal at birth, with multisystem involvement developing over time.
| System | Clinical Manifestations |
|---|---|
| Ocular | Ectopia lentis (lens dislocates downward and inward), severe myopia, glaucoma, retinal detachment. Dislocation usually occurs by 3–4 years of age. |
| Skeletal | Marfanoid habitus, tall stature, arachnodactyly, scoliosis, severe osteoporosis. |
| Vascular | Thromboembolism (represents the major cause of mortality). |
| CNS | Intellectual disability (variable IQ 30–75), psychiatric disorders (anxiety, depression, obsessive-compulsive behavior), seizures in ~20% of patients. |
| Cutaneous | Distinctive malar flush on cheeks, fair skin, and fair hair (hypopigmentation). |
Investigations
Screening Tests
- Cyanide-Nitroprusside Test: Urine turns deep red/magenta, detecting sulfhydryl groups. False negatives can occur with low protein intake, and false positives occur in cystinuria.
- Newborn Screening (NBS): Detects elevated methionine. Note that it may miss B6-responsive forms or remethylation defects where methionine levels are low.
Confirmatory Tests
- Plasma Amino Acids: Classic form shows elevated methionine, elevated homocysteine, and low cysteine. Remethylation defects show low methionine and elevated homocysteine.
- Plasma Total Homocysteine (tHcy): Markedly elevated (>100 µmol/L; Normal <15 µmol/L).
- Enzyme Assay: CBS activity measured in cultured fibroblasts or liver biopsy.
- Genetic Analysis: Mutation analysis of the CBS gene located on chromosome 21q22.3.
Pyridoxine (B6) Challenge Test
- Administer 100–500 mg of Vitamin B6 daily to determine B6 responsiveness (a key prognostic factor).
- A significant drop in plasma homocysteine and methionine implies B6-Responsive Homocystinuria, which carries a milder phenotype.
Management
Specific Therapy
| Therapy | Indication And Rationale |
|---|---|
| Vitamin B6 (Pyridoxine) | First-line for B6-responsive patients (~50%). High dose (200–500 mg/day) aiming to maintain plasma homocysteine <50 µmol/L. Requires co-supplementation with Folate and Vitamin B12 to optimize remethylation. |
| Dietary Restriction | For B6-non-responsive patients. Low methionine diet restricting animal protein (meat, dairy, eggs) and utilizing a methionine-free medical formula containing essential Cysteine. |
| Betaine (Trimethylglycine) | Adjunct for non-responsive cases. Donates a methyl group to remethylate homocysteine to methionine. Requires monitoring to prevent cerebral edema if Methionine exceeds 1000 µmol/L. |
Supportive Care
- Anticoagulation: Not routinely indicated prophylactically, but aggressive intravenous hydration is absolutely mandatory during surgery or illness to prevent thromboembolism.
- Ocular and Skeletal: Regular ophthalmology follow-up for surgical management of dislocated lenses. Calcium and Vitamin D supplementation for bone health.
Prognosis
- Untreated: Poor life expectancy due to severe vascular events, with a 50% mortality rate by age 20–30.
- Treated: B6-responsive patients have an excellent prognosis with normal intelligence and lifespan if treated early. B6-non-responsive patients have good outcomes if diet and Betaine are started in the neonatal period, though late treatment cannot reverse established intellectual disability or lens dislocation.